News

September 20, 2018
Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st
The company and actor join forces to pay homage to those affected by Alzheimer's Disease

DUBLINSept. 20, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced a partnership with actor Scott Eastwood in honor of World Alzheimer's Day, September 21, a day used as a focal point by organizations globally to raise awareness for Alzheimer's disease and the sacrifices caregivers make every day for their loved ones.

Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer’s Day on September 21st

Through combined efforts, Allergan and Scott Eastwood hope to widely deliver the message that it is important for those affected by Alzheimer's to be well-informed, pointing to Allergan's educational website LearnAboutAlz.com as a resource.

Every 65 seconds, someone in the United States develops Alzheimer's disease. For Scott, this was his grandmother, who he lost to the disease before he was even a teenager. In his own experience, Scott remembers his mother assuming the role of a caregiver, while also raising two young children.

"Alzheimer's is an unforgiving disease, and I know firsthand that when someone you love is suffering from it, it is hard to hold on to hope," said Scott Eastwood. "By working with Allergan and their educational initiative LearnAboutAlz.com, I hope to use my platform to show caregivers across the nation that their hard work is not unnoticed, and that there is a community out there and many resources available to support them. We want to encourage people of all ages to learn more about the disease on the website, and to join me by getting involved in the conversation on World Alzheimer's Day on social media."

Allergan launched efforts around LearnAboutAlz.com in December of 2017, offering a host of tips, resources, information about the disease, and treatment options for caregivers, and featuring a powerful video that uses lightbulbs as a metaphor for the disease. Since launch, this spot has been seen by millions of people nationwide, both online and on television.

In June of 2018, the company further extended their message in honor of Alzheimer's & Brain Awareness Month, by partnering with a host of celebrities affected by the disease to tell their stories and honor caregivers for their unwavering efforts. Allergan also proudly works with partners in the Alzheimer's space to help families and patients affected by the disease.

"We are proud to provide treatment options for those suffering with Alzheimer's disease as we continue our efforts to research and develop new treatments. It is also a top priority of ours to provide support for those affected in an effort to make their journey even the slightest bit easier," said Will Kane, senior VP U.S. General Medicine for Allergan. "This World Alzheimer's Day, we are grateful for Scott Eastwood's sharing of his story, and hope to continue collaborating with like-minded individuals to drive awareness about the disease and the burden it puts on patients and their loved ones."

To learn more about Alzheimer's disease, caregiver resources, and treatment options, visit www.LearnAboutAlz.com.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


 

 CONTACTS:   

Allergan:

 

Investors:

 

Daphne Karydas

 

(862) 261-8006

   
 

Karina Calzadilla

 

(862) 261-7328

   
 

Media:

 

Amy Rose

 

(862) 289-3072

   
 

Frances DeSena

 

(862) 261-8820

 

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?